XTL Biopharmaceuticals Ltd.
DB:H2K2 Stock Report
XTL Biopharmaceuticals Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
What is the ownership structure of H2K2?| Owner Type | Number of Shares | Ownership Percentage |
|---|
| Institutions | 26,447,099 | 2.11% |
| Individual Insiders | 131,648,196 | 10.5% |
| General Public | 1,096,247,934 | 87.4% |
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 130.2%.
Top Shareholders
Top 10 shareholders own 12.6% of the company| Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
|---|
| | 128,288,887 | €2.3m | 0% | no data | |
| | 19,888,800 | €348.9k | 0% | 0.04% | |
| Morgan Stanley, Investment Banking and Brokerage Investments | 3,315,100 | €58.2k | -15.4% | no data | |
| | 3,019,309 | €53.0k | 0% | no data | |
| | 1,543,500 | €27.1k | 13.2% | no data | |
| Geode Capital Management, LLC | 883,900 | €15.5k | 1.8% | no data | |
| Rhumbline Advisers Ltd Partnership | 558,400 | €9.8k | 0% | no data | |
| | 340,000 | €6.0k | 0% | no data | |
| | 252,606 | €4.4k | -15.8% | no data | |
| | 4,793 | €83.6 | -97.7% | no data | |
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}